Biofrontera
Price & Volume
Stats
See more52W Range | $0.53-$1.23 |
Market Cap | $9.5M |
Shares Short | 50,833 |
Financials
See moreRevenue (12 Mos) | $37.1M |
Revenue Growth (YoY) | -22.5% |
Gross Profit (12 Mos) | $23.9M |
Diluted EPS | -$1.50 |
News
See moreYahoo Finance • last month
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Yahoo Finance • last month
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
Yahoo Finance • 2 months ago
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
Yahoo Finance • 2 months ago
Biofrontera reports Q3 results
About
CEO | Dr. Hermann Luebbert Ph.D. |
Address | 120 Presidential Way, Woburn, MA, United States, 01801 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 92 |
